These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26564537)

  • 1. Pediatric tuberculosis drug market: an insider perspective on challenges and solutions.
    Usherenko I; Basu Roy U; Mazlish S; Liu S; Benkoscki L; Coutts D; Epstein S; Qian M; Rafiq S; Scott C
    Int J Tuberc Lung Dis; 2015 Dec; 19 Suppl 1():23-31. PubMed ID: 26564537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From availability to uptake: planning for the introduction of new, child-friendly anti-tuberculosis formulations.
    Malhotra S; Ursu I; Ghoneim R; Jodrey PP; Brown MS; Barr-DiChiara M
    Int J Tuberc Lung Dis; 2015 Dec; 19 Suppl 1():32-38. PubMed ID: 26564538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The procurement landscape of pediatric tuberculosis treatment: a Global Drug Facility perspective.
    Scott C; Gardiner E; de Lucia A
    Int J Tuberc Lung Dis; 2015 Dec; 19 Suppl 1():17-22. PubMed ID: 26564536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can Brazil play a more important role in global tuberculosis drug production? An assessment of current capacity and challenges.
    Gemal A; Keravec J; Menezes A; Trajman A
    BMC Public Health; 2013 Mar; 13():279. PubMed ID: 23537151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. India's human rights commission seeks answers over shortage of TB drugs.
    Bhaumik S
    BMJ; 2013 Jul; 347():f4301. PubMed ID: 23824092
    [No Abstract]   [Full Text] [Related]  

  • 6. Requirements for anti-tuberculosis drug tender requests.
    Trébucq A; Caudron JM; Pinel J
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S358-61; discussion S381-7. PubMed ID: 10593718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public health. Responding to market failures in tuberculosis control.
    Gupta R; Kim JY; Espinal MA; Caudron JM; Pecoul B; Farmer PE; Raviglione MC
    Science; 2001 Aug; 293(5532):1049-51. PubMed ID: 11463877
    [No Abstract]   [Full Text] [Related]  

  • 8. Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs.
    Laing RO; McGoldrick KM
    Int J Tuberc Lung Dis; 2000 Dec; 4(12 Suppl 2):S194-207. PubMed ID: 11144553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric TB: issues related to current and future treatment options.
    Marais BJ; Schaaf HS; Donald PR
    Future Microbiol; 2009 Aug; 4(6):661-75. PubMed ID: 19659423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A day in the life of the world's anti-TB drive.
    Davey S
    Bull World Health Organ; 2001; 79(5):486-7. PubMed ID: 11417050
    [No Abstract]   [Full Text] [Related]  

  • 11. How to ensure the continued resurgence of tuberculosis.
    Reichman LB
    Lancet; 1996 Jan; 347(8995):175-7. PubMed ID: 8544556
    [No Abstract]   [Full Text] [Related]  

  • 12. The Global Drug Facility: a unique, holistic and pioneering approach to drug procurement and management.
    Matiru R; Ryan T
    Bull World Health Organ; 2007 May; 85(5):348-53. PubMed ID: 17639218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supplying quality-assured child-friendly anti-tuberculosis drugs to children.
    Gie RP; Matiru RH
    Int J Tuberc Lung Dis; 2009 Mar; 13(3):277-8. PubMed ID: 19275783
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment interruptions and inconsistent supply of anti-tuberculosis drugs in the United Kingdom.
    Capstick TG; Laycock D; Lipman MC;
    Int J Tuberc Lung Dis; 2011 Jun; 15(6):754-60. PubMed ID: 21575294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Global Drug Facility and its role in the market for tuberculosis drugs.
    Arinaminpathy N; Cordier-Lassalle T; Vijay A; Dye C
    Lancet; 2013 Oct; 382(9901):1373-9. PubMed ID: 23726162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of the Indian market of anti-tuberculosis drugs: focus on the utilisation of rifampicin-based products.
    Catalani E
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S289-91; discussion S317-21. PubMed ID: 10593707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'That's when I struggle' … Exploring challenges faced by care givers of children with tuberculosis in Botswana.
    Stillson CH; Okatch H; Frasso R; Mazhani L; David T; Arscott-Mills T; Matlhare M; Steenhoff AP
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1314-1319. PubMed ID: 27725041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Only a fraction of TB patients get the best care.
    J Adv Nurs; 2002 Aug; 39(3):215-6. PubMed ID: 12174835
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of childhood tuberculosis in India.
    Swaminathan S; Sachdeva KS
    Int J Tuberc Lung Dis; 2015 Dec; 19 Suppl 1():43-46. PubMed ID: 26564540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
    Pablos-Mendez A; Gowda DK; Frieden TR
    Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.